Replies to post #94 on Relief Therapeutics Holding AG (RLFTF)

[alexander77]

"VIP is the only pulmonary therapeutic to have been granted Fast Track status by the US FDA and to be allowed into both phase 2/3 clinical trials, as well as an expanded use protocol for those who are unable to enter the clinical trial because of excluded comorbidity."